Brickell Stock Analysis

BBI -  USA Stock  

USD 0.23  0.03  11.54%

The big decline in price over the last few months for Brickell Biotech could raise concerns from stockholders as the firm it trading at a share price of 0.23 on 8,949,325 in volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Brickell Biotech or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 9.1. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Brickell Biotech partners.
Continue to Trending Equities.

Brickell Stock Analysis 

The Brickell Biotech stock analysis report makes it easy to digest most publicly released information about Brickell Biotech and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Brickell Stock analysis module also helps to analyze the Brickell Biotech price relationship with some important fundamental indicators such as market cap and management efficiency.

Brickell Stock Analysis Notes

About 16.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.04. Some equities with similar Price to Book (P/B) outperform the market in the long run. Brickell Biotech recorded a loss per share of 0.62. The entity had not issued any dividends in recent years. The firm had a split on the 3rd of September 2019. Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company was founded in 2009 and is headquartered in Boulder, Colorado. Brickell Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. For more info on Brickell Biotech please contact Garth Braun at 720 505 4755 or go to

Brickell Biotech Quarterly Cost of Revenue


Brickell Biotech Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Brickell Biotech's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Brickell Biotech or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Brickell Biotech generated a negative expected return over the last 90 days
Brickell Biotech has high historical volatility and very poor performance
Brickell Biotech has some characteristics of a very speculative penny stock
Brickell Biotech has high likelihood to experience some financial distress in the next 2 years
Brickell Biotech was previously known as Vical Inc and was traded on NAS Exchange under the symbol VICL.
The company reported the last year's revenue of 327 K. Reported Net Loss for the year was (40.77 M) with loss before taxes, overhead, and interest of (9.39 M).
Brickell Biotech has about 21.38 M in cash with (36.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19.
Brickell Biotech has a poor financial position based on the latest SEC disclosures
Latest headline from You Need to Know this stock Brickell Biotech, - The Union Journal

Brickell Biotech Upcoming and Recent Events

Earnings reports are used by Brickell Biotech to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Brickell Biotech previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report8th of March 2022
Next Earnings Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End8th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Brickell Largest EPS Surprises

Earnings surprises can significantly impact Brickell Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Brickell Biotech SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Brickell Biotech prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Brickell Biotech investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Brickell Biotech specific information freely available to individual and institutional investors to make a timely investment decision.
14th of December 2021
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
9th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
3rd of November 2021
Unclassified Corporate Event
1st of November 2021
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
7th of October 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
1st of September 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Unregistered Sales of Equity Securities. Completion of Acquisition or Disposition of Assets. Entry into a Material Definitive Agreement
12th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
22nd of July 2021
Financial Statements and Exhibits. Other Events. Unclassified Corporate Event. Entry into a Material Definitive Agreement

Brickell Biotech Thematic Classifications

In addition to having Brickell Biotech stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Brickell Market Capitalization

The company currently falls under 'Micro-Cap' category with total capitalization of 26.81 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Brickell Biotech's market, we take the total number of its shares issued and multiply it by Brickell Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Brickell Profitablity

Brickell Biotech's profitability indicators refer to fundamental financial ratios that showcase Brickell Biotech's ability to generate income relative to its revenue or operating costs. If, let's say, Brickell Biotech is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Brickell Biotech's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Brickell Biotech's profitability requires more research than a typical breakdown of Brickell Biotech's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.75) (0.77) 
Return on Average Equity(1.05) (1.08) 
Return on Invested Capital 18.21  19.65 
Return on Sales(10.33) (10.60) 

Management Efficiency

The entity has Return on Asset of (102.14) % which means that on every $100 spent on asset, it lost $102.14. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (210.82) %, meaning that it generated no profit with money invested by stockholders. Brickell Biotech management efficiency ratios could be used to measure how well brickell biotech manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Invested Capital is estimated to increase to 19.65, while Return on Average Assets are projected to decrease to (0.77) . Brickell Biotech Assets Non Current are most likely to decrease significantly in the upcoming years. The last year's value of Assets Non Current was reported at 93,600. The current Goodwill and Intangible Assets is estimated to increase to about 407.3 K, while Return on Average Assets are projected to decrease to (0.77) .
Last ReportedProjected for 2022
Book Value per Share 1.00  1.03 
Enterprise Value over EBIT(1.15) (1.24) 
Enterprise Value over EBITDA(1.21) (1.31) 
Price to Book Value 1.39  1.41 
Tangible Assets Book Value per Share 1.23  1.26 
Enterprise Value19.8 M20.4 M
Tangible Asset Value30.3 M37.8 M

Technical Drivers

As of the 26th of January, Brickell Biotech shows the mean deviation of 4.9, and Risk Adjusted Performance of (0.07). Brickell Biotech technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed nineteen technical drivers for Brickell Biotech, which can be compared to its rivals. Please confirm Brickell Biotech standard deviation, value at risk, kurtosis, as well as the relationship between the jensen alpha and semi variance to decide if Brickell Biotech is priced correctly, providing market reflects its regular price of 0.23 per share. As Brickell Biotech appears to be a penny stock we also recommend to validate its total risk alpha numbers.

Brickell Biotech Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Simple Moving Average indicator is calculated by adding the closing price of Brickell Biotech for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Brickell Biotech short-term fluctuations and highlight longer-term trends or cycles. View also all equity analysis or get more info about simple moving average overlap studies indicator.

Brickell Biotech Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Brickell Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Brickell Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Brickell Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Luchi Monica E over three months ago via Macroaxis 
Acquisition by Luchi Monica E of 400000 shares of Brickell Biotech subject to Rule 16b-3
Mcavoy David R over six months ago via Macroaxis 
Brickell Biotech exotic insider transaction detected
Chadha Deepak over six months ago via Macroaxis 
Acquisition by Chadha Deepak of 250000 shares of Brickell Biotech subject to Rule 16b-3
Chadha Deepak over six months ago via Macroaxis 
Purchase by Chadha Deepak of 12500 shares of Brickell Biotech
Chadha Deepak over six months ago via Macroaxis 
Exercise or conversion by Chadha Deepak of 25000 shares of Brickell Biotech subject to Rule 16b-3
Samant Vijay B over a year ago via Macroaxis 
Payment of 4408 shares by Samant Vijay B of Brickell Biotech subject to Rule 16b-3
Mcavoy David R over a year ago via Macroaxis 
Purchase by Mcavoy David R of 6000 shares of Brickell Biotech
Mcavoy David R over a year ago via Macroaxis 
Acquisition by Mcavoy David R of 350000 shares of Brickell Biotech subject to Rule 16b-3
Chadha Deepak over a year ago via Macroaxis 
Acquisition by Chadha Deepak of 400000 shares of Brickell Biotech subject to Rule 16b-3
Veru Dennison T over a year ago via Macroaxis 
Exercise or conversion by Veru Dennison T of 788 shares of Brickell Biotech subject to Rule 16b-3
Lyons Gary A over a year ago via Macroaxis 
Exercise or conversion by Lyons Gary A of 692 shares of Brickell Biotech subject to Rule 16b-3
Hardy Reginald L over a year ago via Macroaxis 
Payment of 283 shares by Hardy Reginald L of Brickell Biotech subject to Rule 16b-3

Brickell Biotech Technical and Predictive Indicators

Brickell Biotech Forecast Models

Brickell Biotech time-series forecasting models is one of many Brickell Biotech's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Brickell Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Brickell Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Brickell Biotech stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Brickell shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Brickell Biotech. By using and applying Brickell Stock analysis, traders can create a robust methodology for identifying Brickell entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(10.33) (10.60) 
Gross Margin 1.15  1.24 
Profit Margin(10.33) (10.60) 
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company was founded in 2009 and is headquartered in Boulder, Colorado. Brickell Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Brickell Biotech to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Fundamentals Comparison Now


Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
All  Next Launch Module
Continue to Trending Equities. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.